1-5 of 5
Rita Mitlohner
Close
Sort by
Journal Articles

Intermediate-Risk Acute Lymphoblastic Leukemia (ALL) Patients with and without Relapse Differentially Depend on Survival Signals From Microenvironment

Peter Rhein, PhD, Rita Mitlohner, Renate Kirschner-Schwabe, PhD, Christian Hagemeier, MD, PhD, Gunnar Cario, MD, Martin Stanulla, MD, MSc, Martin Schrappe, MD, Iduna Fichtner, PhD, Richard Ratei, MD, Wolf-Dieter Ludwig, Leonid Karawajew, PhD
Journal: Blood
Blood (2011) 118 (21): 752.
https://doi.org/10.1182/blood.V118.21.752.752
Published: 2011
Journal Articles

High CD45 (PTPRC) Expression Is Associated with An Overall Poor Outcome in Childhood Acute Lymphoblastic Leukemia Treated on the ALL-BFM 2000 Protocol and Exerts An Especially Pronounced Effect in Intermediate Risk Patients

Gunnar Cario, MD, Rita Mitlohner, Martin Zimmermann, PhD, Renja Romey, Peter Rhein, PhD, André Schrauder, MD, Anja Moericke, MD, Jean-Pierre Bourquin, MD, PhD, Wolf-Dieter Ludwig, MD, Richard Ratei, MD, Martin Schrappe, MD, Leonid Karawajew, PhD, Martin Stanulla, MD, MSc
Journal: Blood
Blood (2011) 118 (21): 742.
https://doi.org/10.1182/blood.V118.21.742.742
Published: 2011
Journal Articles

CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia

Peter Rhein, Rita Mitlohner, Giuseppe Basso, Giuseppe Gaipa, Michael N. Dworzak, Renate Kirschner-Schwabe, Christian Hagemeier, Martin Stanulla, Martin Schrappe, Wolf-Dieter Ludwig, Leonid Karawajew, Richard Ratei
Journal: Blood
Blood (2010) 115 (18): 3763–3771.
https://doi.org/10.1182/blood-2009-10-247585
Published: 2010
Journal Articles

Integrin Alpha M Chain Expression at Diagnosis Is Inversely Correlated with Cytoreduction Rate and Is Consistently Up-Regulated during Therapy in Acute Lymphoblastic Leukemia (ALL)

Peter Rhein, Richard Ratei, MD, Rita Mitlohner, Giuseppe Basso, MD, Giuseppe Gaipa, MD, Michael N Dworzak, MD, PhD, Martin Stanulla, MD, Martin Schrappe, MD, Wolf-Dieter Ludwig, MD, Leonid Karawajew, PhD
Journal: Blood
Blood (2008) 112 (11): 2526.
https://doi.org/10.1182/blood.V112.11.2526.2526
Published: 2008
Journal Articles

CD11b Is a Therapy-Induced Marker for Monitoring Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia.

Peter Rhein, Richard Ratei, M.D., Rita Mitlohner, Martin Schrappe, M.D., Wolf-Dieter Ludwig, M.D., Leonid Karawajew, Ph.D.
Journal: Blood
Blood (2007) 110 (11): 1424.
https://doi.org/10.1182/blood.V110.11.1424.1424
Published: 2007